Author:
Zaun Gregor,Borchert Sabrina,Metzenmacher Martin,Lueong Smiths,Wiesweg Marcel,Zaun Yasmin,Pogorzelski Michael,Behrens Franziska,Schildhaus Hans-Ulrich,Virchow Isabel,Kasper Stefan,Schuler Martin,Theurer Sarah,Liffers Sven
Funder
Universität Duisburg-Essen
Reference23 articles.
1. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Krämer;Ann Oncol,2024
2. SUVmax Above 20 in 18F-FDG PET/CT at initial diagnostic workup associates with favorable survival in patients with cancer of unknown primary;Zaun;J Nucl Med,2023
3. CUP Syndrome;Zaun;Metastatic Malig Unkn Prim Tumor Dtsch Arztebl Int,2018
4. Impact of targeted therapy on the survival of patients with advanced-stage non-small cell lung cancer in oncosalud - AUNA;Aguilar;Cancer Control,2022
5. FDA approval: Entrectinib: FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC: 08/16/2019: 〈https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc〉.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献